Market Overview
Global Mycobacterium Infections Treatment market was valued at USD 1,979 million in 2024. The market is projected to grow from USD 2,053 million in 2025 to USD 2,375 million by 2031, exhibiting a CAGR of 2.7% during the forecast period.
Mycobacterium infections encompass chronic granulomatous diseases caused by acid-fast bacteria, including tuberculosis (TB) and non-tuberculous mycobacterial (NTM) infections. These pathogens are characterized by their complex cell wall structure containing mycolic acids, which contributes to their resistance against standard antimicrobial treatments. The treatment landscape includes first-line drugs like isoniazid and rifampin, along with second-line therapies for drug-resistant strains.
USD 1,979 million in 2024
USD 2,375 million by 2031
CAGR of 2.7%
Oral Segment Dominates the Market Due to its Convenience and Widespread Use in Long-Term Tuberculosis Therapy
The market is segmented based on type into:
Oral Injection
The oral segment holds the largest share owing to the preference for non-invasive administration in outpatient settings, facilitating patient compliance in chronic treatment scenarios. Injectable formulations, while essential for severe cases or when oral intake is not feasible, are typically reserved for hospital-based interventions.
By
Application
The market is segmented based on application into:
Hospitals
Specialty Clinics
Other Hospitals dominate as primary treatment hubs for acute and resistant infections, equipped with specialized infrastructure for monitoring therapy outcomes.
Portable Neuromonitoring Device Market
Specialty clinics contribute significantly in follow-up care and management of nontuberculous infections, while other applications include community health programs and research facilities.
Our Key Players
F. Hoffmann-La Roche Ltd
Mylan N.V
https://www.24lifesciences.com/dow
https://www.24lifesciences.com
